Table 2.

Clinical benefits and quality of life

	Group (number of patients)
	All (178)	Etanercept (106)	Adalimumab (57)	Infliximab (15)
HR-QOL
Enrolment	0.58	0.62	0.52	0.60
Δ	0.23	0.23	0.21	0.21
p value*	0.000	0.000	0.000	0.001
VAS
Enrolment	57.06	60.29	49.96	61.20
Δ	19.89	19.03	23.51	12.20
p value*	0.000	0.000	0.000	0.009
PASI
Enrolment	21.57	23.58	17.98	21.01
Δ	12.58	14.35	9.77	10.76
p value*	0.000	0.000	0.000	0.006
Pain VAS
Enrolment	28.43	31.45	24.21	25.53
Δ	19.63	23.70	14.47	12.07
p value*	0.000	0.000	0.000	0.142
Itching VAS
Enrolment	31.71	34.04	27.09	32.87
Δ	24.06	26.86	18.84	24.13
p value*	0.000	0.000	0.000	0.009

HR-QOL health-related quality of life, PASI Psoriasis Area and Severity Index, VAS visual analogue score

* Paired T test